Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: AXIM

AXIM Biotech Cannabis Chewing Gum Plans to Enter General Pain Market


According to the National Institute of Health, pain impacts more people in the United States than cancer, heart disease and diabetes. Research shows that chronic pain is the leading cause of long-term disability, and it is also the most common reason for entering the health care system. Despite the great financial and personal costs associated with pain, this is a significantly underserved market in the United States and around the world. While there are many prescription drugs available on the market for the treatment of pain, many are either ineffective at managing acute or chronic pain or come with debilitating side effects.

Pain and the Opioid Epidemic

Opioid addiction affects between 26.4 and 36 million people around the world each year. The opioid epidemic has reached global crisis levels, and world leaders have launched various initiatives to help reduce reliance on these highly addictive drugs. While opioids are often effective …

Continue Reading

Posted in Articles| Tagged , |

AXIM IBS Treatment Options and Market Growth in 2017 and Beyond


Irritable bowel syndrome is a chronic condition characterized by discomfort and pain in the abdominal region. Sufferers also experience symptoms such as diarrhea, constipation and gas, and it is believed that the condition is adversely affected by anxiety. Anywhere between 25 and 45 million people are affected by IBS in the United States alone, and 2 out of 3 IBS patients are women. The unfortunate reality for IBS sufferers is that there are few effective long-term treatments that manage symptoms without the risk of side effects. As a result, the IBS market presents plenty of opportunities for alternative treatment methods to make a positive impact on patients worldwide.

Medical Marijuana Products

Pharmaceutical industry experts predict that the market for cannabis products could reach 10 percent of the specialty market by the year 2020, with a market value of $20 billion. With a variety of cannabinoids to test and incorporate …

Continue Reading

Posted in Articles| Tagged , , , , |

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum at Wageningen University in the Netherlands.

The research team previously received approval from the Medical Ethical Committee (METC) of Wageningen University to study novel treatments for patients suffering from IBS. Functional, controlled-release Hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies. The amount of the Hemp oil CBD gum is set at 50 mg CBD per serving. According to the trial protocol patients can use up to 6 chewing gums a day to control their stomach cramps, bloating, pain and other symptoms. The main study outcome is perceived pain reduction. Furthermore, the study will record general relief and change in stool frequency.

Designed by …

Continue Reading

Posted in Client News| Tagged |

Meet the Newest Cannabis Industry Experts to Join the AXIM Advisory Board

AXIM Biotechnologies

Success begins with strategic partnership, and AXIM Biotechnologies, Inc. (OTCQB: AXIM) is poised for continued success thanks to the decision to partner with several cannabis industry experts. These experts will join the AXIM Advisory Board to provide their perspectives on company progress and future decisions. The AXIM Advisory Board is now proud to include Dr. Ilya Reznik, Professor Renger Witkamp, and Professor John Zajicek.

The AXIM Advisory Board

The AXIM Advisory Board is a team comprised of some of the brightest minds in the industry with members from all over the world. These experts bring their years of industry knowledge and experience to the table to help the company improve on its current successes and lay the foundations for an even more promising future. A strong Board is the key to making informed decisions in a rapidly changing market. From advisement on product pipeline innovations and technological advances to …

Continue Reading

Posted in Articles| Tagged , , , |

AXIM is Setting the Pace in Brave New Markets

AXIM Biotechnologies

AXIM Biotech has recently made headlines with the filing of an IP application for a unique method to extract THC from cannabis. The most unique aspect of this proprietary extraction technique is that it is capable of extracting 95 percent of pure THC content from cannabis. This patent will allow AXIM to make revolutionary gains in medical marijuana research. Previously, it has been difficult for scientists to conduct research on THC as it has not been extracted as a stand-alone compound. AXIM‘s new extraction technique will allow the company’s research and development team to gain greater control during studies that test its effectiveness under different concentrations and conditions.

About THC Extraction

The IP application, filed with the World Intellectual Property Organization, is designed specifically to extract tetrahydrocannabinol acid from cannabis. This makes it possible to create formulations that are more highly concentrated than those created with traditional extraction methods. …

Continue Reading

Posted in Articles| Tagged , , |

Dr. George E. Anastassov, Chief Executive Officer of AXIM® Biotech, Featured in Exclusive Interview with

AUSTIN, Texas, Nov. 30, 2016 (GLOBE NEWSWIRE) —, Inc. (SCV) and AXIM® Biotechnologies, Inc. (AXIM®Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company’s Chief Executive Officer, George E. Anastassov, is featured in an audio interview at The interview outlining the company’s business strategy and future is now available and can be heard at

George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech, called in to to discuss the company’s business model, target markets and exciting recent news. The Company recently announced that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods.

George E. Anastassov commented, “Our unique opportunities in several new market segments were able to be detailed in this …

Continue Reading

Posted in Client News| Tagged , , |